Nothing Special   »   [go: up one dir, main page]

Contaldi et al., 2023 - Google Patents

Disease mechanisms as subtypes: Immune dysfunction in Parkinson's disease

Contaldi et al., 2023

Document ID
13744473370063300002
Author
Contaldi E
Magistrelli L
Comi C
Publication year
Publication venue
Handbook of Clinical Neurology

External Links

Snippet

In recent years, the contraposition between inflammatory and neurodegenerative processes has been increasingly challenged. Inflammation has been emphasized as a key player in the onset and progression of Parkinson disease (PD) and other neurodegenerative …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Similar Documents

Publication Publication Date Title
Needham et al. The immunological response to traumatic brain injury
Milovanovic et al. Interleukin-17 in chronic inflammatory neurological diseases
Mayne et al. Aging and neurodegenerative disease: is the adaptive immune system a friend or foe?
Tansey et al. Immune system responses in Parkinson's disease: early and dynamic
Appel et al. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?
Anderson et al. Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders
Pizza et al. Neuroinflamm-aging and neurodegenerative diseases: an overview
Pérez et al. Interleukin‐17/interleukin‐17 receptor axis elicits intestinal neutrophil migration, restrains gut dysbiosis and lipopolysaccharide translocation in high‐fat diet‐induced metabolic syndrome model
Stone et al. Innate and adaptive immunity for the pathobiology of Parkinson's disease
Zheng et al. Paeoniflorin ameliorates ulcerative colitis by modulating the dendritic cell-mediated TH 17/T reg balance
das Neves et al. Altered astrocytic function in experimental neuroinflammation and multiple sclerosis
Ghosh et al. Cellular and molecular influencers of neuroinflammation in Alzheimer's disease: recent concepts & roles
Hagen et al. The neuroimmunology of Guillain-Barré syndrome and the potential role of an aging immune system
Ingwersen et al. Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis
Hayashi et al. The role of caspase cascade on the development of primary Sjogren's syndrome
Perera et al. Active immunization with myelin-derived altered peptide ligand reduces mechanical pain hypersensitivity following peripheral nerve injury
Mamais et al. Convergence of signalling pathways in innate immune responses and genetic forms of Parkinson’s disease
US11567078B2 (en) Blood cell biomarker for late onset Alzheimer's disease
Li et al. γδ T cells participating in nervous systems: a story of Jekyll and Hyde
He et al. Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1β and IL-12 in NOD mice
Contaldi et al. Disease mechanisms as subtypes: Immune dysfunction in Parkinson's disease
Tamouza et al. Possible effect of the use of mesenchymal stromal cells in the treatment of autism spectrum disorders: a review
MA Mechanisms of immune regulation in Alzheimer’s disease: a viewpoint
Pletz et al. Immune-mediated neuropathies: etiology and pathogenic relationship to aging processes
Dionisio-Santos Ameliorating Alzheimer’s Disease Tau Pathology Through Immunomodulation: A Novel Role for Interleukin 4 and Glatiramer Acetate